NEW YORK, April 09, 2019 (GLOBE NEWSWIRE) -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of Wyndham Hotels & Resorts Inc. (NYSE:WH), Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Transcat, Inc. (NASDAQ:TRNS), Emerald Expositions Events, Inc. (NYSE:EEX), Capitala Finance Corp. (NASDAQ:CPTA), and Seres Therapeutics, Inc. (NASDAQ:MCRB), including updated fundamental summaries, consolidated fiscal reporting, and fully-qualified certified analyst research.
The new research reports from Capital Review, available for free download at the links above, examine Wyndham Hotels & Resorts Inc. (NYSE:WH), Apellis Pharmaceuticals, Inc. (NASDAQ:APLS), Transcat, Inc. (NASDAQ:TRNS), Emerald Expositions Events, Inc. (NYSE:EEX), Capitala Finance Corp. (NASDAQ:CPTA), and Seres Therapeutics, Inc. (NASDAQ:MCRB) on a fundamental level and outlines the overall demand for their products and services in addition to an in-depth review of the business strategy, management discussion, and overall direction going forward. Several excerpts from the recently released reports are available to today's readers below.
For the three months ended December 31st, 2018 vs December 31st, 2017, Wyndham Hotels & Resorts reported revenue of $527.00MM vs $313.00MM (up 68.37%) and analysts estimated basic earnings per share $0.83 vs $1.25 (down 33.60%). For the twelve months ended December 31st, 2018 vs December 31st, 2017, Wyndham Hotels & Resorts reported revenue of $1,868.00MM vs $1,280.00MM (up 45.94%) and analysts estimated basic earnings per share $1.62 vs $2.31 (down 29.87%). Analysts expect earnings to be released on April 30th, 2019. The report will be for the fiscal period ending March 31st, 2019. The estimated EPS forecast for the next fiscal year is $3.60 and is expected to report on February 12th, 2020.
Analysts expect earnings to be released on April 29th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was -$0.43. The estimated EPS forecast for the next fiscal year is -$3.31 and is expected to report on February 25th, 2020.
For the three months ended December 31st, 2018 vs December 31st, 2017, Transcat reported revenue of $40.87MM vs $40.48MM (up 0.95%) and analysts estimated basic earnings per share $0.22 vs $0.26 (down 15.38%). For the twelve months ended March 31st, 2018 vs March 31st, 2017, Transcat reported revenue of $155.14MM vs $143.90MM (up 7.81%) and analysts estimated basic earnings per share $0.83 vs $0.65 (up 27.69%). Analysts expect earnings to be released on May 28th, 2019. The report will be for the fiscal period ending March 31st, 2019. Reported EPS for the same quarter last year was $0.27. The estimated EPS forecast for the next fiscal year is $1.01 and is expected to report on May 28th, 2019.
For the three months ended December 31st, 2018 vs December 31st, 2017, Emerald Expositions Events reported revenue of $57.00MM vs $31.50MM (up 80.95%) and basic earnings per share -$1.23 vs $0.55. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Emerald Expositions Events reported revenue of $380.70MM vs $341.70MM (up 11.41%) and analysts estimated basic earnings per share -$0.34 vs $1.19. Analysts expect earnings to be released on May 2nd, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.66. The estimated EPS forecast for the next fiscal year is $1.16 and is expected to report on February 13th, 2020.
For the three months ended December 31st, 2018 vs December 31st, 2017, Capitala Finance reported revenue of $15.66MM vs $18.74MM (down 16.46%) and analysts estimated basic earnings per share -$0.58 vs -$0.04. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Capitala Finance reported revenue of $51.64MM vs $58.23MM (down 11.32%) and analysts estimated basic earnings per share -$1.00 vs -$0.44. Analysts expect earnings to be released on May 6th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was $0.28. The estimated EPS forecast for the next fiscal year is $1.00 and is expected to report on March 2nd, 2020.
For the three months ended December 31st, 2018 vs December 31st, 2017, Seres Therapeutics reported revenue of $10.63MM vs $3.06MM (up 247.81%) and analysts estimated basic earnings per share -$0.52 vs -$0.72. For the twelve months ended December 31st, 2018 vs December 31st, 2017, Seres Therapeutics reported revenue of $28.27MM vs $32.10MM (down 11.94%) and analysts estimated basic earnings per share -$2.43 vs -$2.21. Analysts expect earnings to be released on May 8th, 2019. The report will be for the fiscal period ending March 31st, 2019. The reported EPS for the same quarter last year was -$0.69. The estimated EPS forecast for the next fiscal year is -$2.10 and is expected to report on March 4th, 2020.